DULISCO (Dutch Life Sciences Cöoperatie UA)

What DULISCO (Dutch Life Sciences Cöoperatie UA) does

DULISCO (Dutch Life Sciences Coöperatie U.A.) is a privately held Dutch cooperative founded in 2019 and headquartered in 's-Hertogenbosch, Netherlands. It operates as a lean life sciences acceleration vehicle (5 employees) serving Dutch family offices, selecting life sciences businesses with social impact and sustainable potential, and providing them with services across business development, intellectual property, finance, and marketing/communication. Its mission is to maximize the full potential of member companies to ultimately improve patient treatment through professionalization, network expansion, and hands-on strategic and operational management.

The cooperative's portfolio comprises five specialized life sciences companies, each anchored by a proprietary technology platform. Pepscan (acquired by Biosynth Carbosynth in July 2022) provided ISO 9001:2015 certified integrated peptide services using the proprietary CLIPS (Chemical Linkage of Peptides onto Scaffolds) technology for peptide constraining, with applications in epitope mapping, antibody services, and GMP peptide production. PamGene operates an array-based kinome profiling platform and the ISO 13485:2016 certified IOpener blood-based diagnostic for predicting immunotherapy response. Glycostem Therapeutics develops oNKord, an off-the-shelf allogeneic NK cell therapy derived from umbilical cord blood stem cells, which received FDA Orphan Drug Designation for Multiple Myeloma in October 2020 and is in Phase I/IIa trials for AML across 5 European countries. Catapult Therapeutics is developing CAP-100, a first-in-class humanized anti-CCR7 antibody that received FDA IND clearance in February 2021. Watermelon provides customer service chatbot software.

DULISCO's business model centers on providing professional services to its member companies rather than generating direct product revenue. The cooperative monetizes through service fees, shared expertise, and the strategic value created across its portfolio, with member companies independently commercializing their products through enterprise B2B channels including licensing deals (Bicycle Therapeutics global CLIPS license), co-development partnerships (Fusion Pharmaceuticals, Evaxion, Zelluna Immunotherapy, BiOrion, Viewpoint Molecular Targeting), and government/non-dilutive funding (€19M raised by Glycostem including Dutch Government Innovation Credit; Eurostars grant for PRECISE). Key certifications include ISO 9001:2015 (Pepscan), ISO 13485:2016 (PamGene), and FDA Orphan Drug Designation plus IND clearance for portfolio products. The advisory board includes Dr. Wiebe Olijve, who led the project that discovered pembrolizumab (Keytruda) at Organon, and Prof. Dr. Bob Pinedo, former Director of VUmc Cancer Center Amsterdam with 650+ peer-reviewed publications.

Name

DULISCO (Dutch Life Sciences Cöoperatie UA)

Legal name

Dutch Life Sciences Coöperatie U.A.

Website

https://dulisco.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

DULISCO (Dutch Life Sciences Coöperatie UA) is a privately held Dutch cooperative that accelerates life sciences companies by providing business, IP, finance, and marketing services to a portfolio of five specialized member companies in peptides, kinome profiling, NK cell therapy, antibody therapeutics, and customer service software.

Ownership category

akta.pro rank

Product category

Life Sciences Acceleration Services

NAICS

Other Management Consulting Services (541618), Management Consulting Services (54161), Professional, Scientific, and Technical Services (54)

SIC

Services-Management Consulting Services (8742), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Sustainability & ESG Consulting (BPAHACAK)

Keywords

• Life sciences acceleration
• Peptide synthesis services
• Cooperative venture building
• Cell therapy development
• Kinome profiling services

Headquarters

HQ city

's-Hertogenbosch

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Services to Member Companies: DULISCO provides services to life sciences companies by onboarding skills in business, intellectual property, finance and marketing and communication. Operates collaboratively with Dutch family offices.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

DULISCO is a Dutch cooperative (Coöperatie U.A.) that accelerates member life sciences companies by providing professionalization services in business, intellectual property, finance, and marketing/communication. It operates for Dutch family offices, selecting businesses with social impact and sustainable growth potential, and provides hands-on strategic and operational management through a lean team of specialists. The cooperative portfolio includes Pepscan (peptide services), PamGene (kinome profiling diagnostics), Glycostem (NK cell therapy), Catapult Therapeutics (antibody therapy), and Watermelon (customer service software).

Product overview

DULISCO (Dutch Life Sciences Coöperatie UA) is a life sciences acceleration cooperative, not a single product company. The organization operates by onboarding portfolio companies (Catapult Therapeutics, Glycostem Therapeutics, Pepscan, PamGene, and Watermelon) and providing them with business expertise, intellectual property guidance, finance support, and marketing/communication services. The portfolio includes: Pepscan (ISO 9001:2015 certified peptide services provider using proprietary CLIPS™ technology); PamGene with its IOpener® diagnostic test (ISO 13485:2016 certified kinome profiling); Glycostem's oNKord® (NK cell therapy with FDA Orphan Drug Designation); Catapult Therapeutics' CAP-100 (anti-CCR7 antibody with FDA IND clearance); and Watermelon (customer service software).

Differentiator

Problem solved

Functional benefit

Products and services

• DULISCO Acceleration Services Core cooperative service providing professionalization, network expansion, intellectual property, finance, and marketing/communication support to life sciences member companies, with hands-on strategic and operational management delivered by a lean team of specialists.
• Pepscan Peptide Services
• PamGene IOpener Immunotherapy Selection Test
• Glycostem oNKord NK Cell Therapy
• Catapult Therapeutics CAP-100 Antibody
• Watermelon Customer Service Software

Quantifiable outcome

• Glycostem's oNKord® showed no toxicity, expanded in vivo, migrated to bone marrow and killed leukemic blasts in Phase I study with AML patients
• +2 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core.

• Evaxion BiotechcoreStrategic or Co-development Partner · 18 March 2022Pepscan manufactures personalized peptide pools for Evaxion's Phase IIb trial of EVX-01 personalized cancer therapy. Previously successfully supplied Phase I/IIa trial for metastatic melanoma patients.
• Fusion PharmaceuticalscoreStrategic or Co-development Partner · 13 January 2022Strategic research collaboration to discover novel peptide-based radiopharmaceuticals for solid tumors. Pepscan's CLIPS phage display platform screens billions of peptides to discover constrained de novo peptides for Fusion's targeted alpha therapies.
• Ardigen and ImmuMapcoreStrategic or Co-development Partner · 8 July 2021AI-based TCRact technology collaboration for designing and optimizing T-cell receptors for cancer immunotherapies. Partly funded by EU's European Regional Development Fund.
• Viewpoint Molecular TargetingcoreStrategic or Co-development Partner · 7 July 2021Partnership for peptide discovery program for precision lead-212-based alpha-particle oncology therapeutics and complementary diagnostic imaging agents. Pepscan's CLIPS technology for superior synthetic peptide candidates.
• Novigenix and Radboud University Medical CentercoreStrategic or Co-development Partner · 1 July 2021PRECISE consortium awarded Eurostars grant of up to €1 million to develop in-vitro diagnostic liquid biopsy test for bladder cancer immunotherapy response prediction. Combines PamGene's kinome profiling with Novigenix and Radboud expertise.
• Bicycle TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 20 November 2020Global CLIPS Technology license agreement for Bicycle's product candidates BT1718 and THR-149. Includes settlement of all intellectual property disputes worldwide. CLIPS-peptides offer enhanced affinity, selectivity and proteolytic stability.
• BiOrioncoreStrategic or Co-development Partner · 3 July 2020Pepscan manufactured GMP-grade conjugate-peptide for BiOrion's clinical trial targeting fibrotic diseases using PDGF-β-receptor interference therapy.
• Zelluna ImmunotherapycoreStrategic or Co-development Partner · 19 November 2019Development, license and supply agreement for allogeneic TCR guided NK-cell therapies (TCR-NK) for cancer treatment. Zelluna leads development and commercialization with TCRs; Glycostem manufactures clinical grade NK-cells and provides expertise, process development, and clinical/commercial supply.
• Korean Pharmaceutical Company (Undisclosed)coreStrategic or Co-development Partner · 11 September 2019Two agreements: exclusive commercialization of oNKord for Korea and Japan, and co-development agreement for CAR-NK product with global commercialization rights for the Korean partner.
• European Partners (Undisclosed)coreStrategic or Co-development Partner · 25 June 2019Pepscan produced clinical neoantigen peptides tailored to individual patient tumors for collaborative personalized anti-cancer vaccine trial.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Regional players

• HealthCap: European life sciences investor with a portfolio approach across therapeutic areas — comparable as a multi-asset life sciences investment platform serving similar biotech founders.
• Forbion: Leading Dutch life sciences venture capital firm with deep Benelux portfolio — most direct geographic peer and potential strategic partnership opportunity for DULISCO's portfolio companies.
• BioGeneration Ventures (BGV): Dutch venture capital firm focused on early-stage life sciences companies — overlaps with DULISCO's Dutch-based portfolio acceleration and investor engagement.
• V-Bio Ventures: Belgian early-stage life sciences investor supporting biotech companies from lab to clinical proof-of-concept — overlaps with DULISCO's acceleration and operational support activities.
• Medicxi: European life sciences investment firm focused on asset-centric biotech — comparable to DULISCO's approach of building/accelerating multiple specialized life sciences companies.

Direct peers

• PureTech Health: Boston/London-listed platform company that develops and accelerates a portfolio of life sciences companies — directly comparable to DULISCO's cooperative acceleration model across multiple therapeutic modalities.
• Roivant Sciences: Operates a federation of biotech Vants focused on different therapeutic areas, providing shared operational and capital infrastructure — analogous to DULISCO's multi-portfolio acceleration model.
• Arix Bioscience: European life sciences investment platform backing and building biotech companies — comparable as a holding/investment vehicle for life sciences ventures with shared operational support.

Broad incumbents

• BB Biotech: Swiss-listed biotech holding company investing globally in innovative life sciences companies — comparable as a diversified biotech investment vehicle, though at much larger scale.

Emerging players

• BridgeBio Pharma: Clinical-stage biotechnology company that builds a portfolio of programs around genetically validated targets — shares multi-asset platform structure with DULISCO's portfolio companies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dulisco

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DULISCO (Dutch Life Sciences Cöoperatie UA)